The collaboration will leverage Alligator's proprietary patient specific immunotherapy Neo-X-Prime and incorporate MacroGenics' proprietary Dart and Trident multispecific platforms against two undisclosed targets. Neo-X-Prime is used for the development of personalized immunotherapy and physically links circulating tumor material to the immune system to allow neoantigen-specific T-cell priming. The Dart and Trident platforms enable the creation of bispecific molecules (those that simultaneously bind two targets).

Under the joint research collaboration, including activities leading up to investigational new drug application-enabling studies, each company will be responsible for its own costs. The companies may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.

Alligator launches new human antibody library
Alligator Bioscience has launched a new human antibody library in fragment antigen-binding format.

Alligator, Scandion pursue preclinical immunotherapies
Sweden-based Alligator Bioscience and Scandion Oncology inked an agreement to explore the antitumor efficacy of CD40 antibody mitazalimab in combination...